Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSD | P07339 | 9/20 | 0.51 |
| ▸ | BACE1 | P56817 | 9/20 | 0.43 |
| ▸ | ADAM17 | P78536 | 1/20 | 0.38 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.35 |
| ▸ | CPB2 | Q96IY4 | 1/20 | 0.34 |
| ▸ | REN | P00797 | 1/20 | 0.34 |
| ▸ | TERF2 | Q15554 | 1/20 | 0.33 |
| ▸ | GAA | P10253 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15750383 | 1.00 | CTSD (0.51) | CTSDBACE1ADAM17EPHX1CPB2 | |
| SCHEMBL15727227 | 0.96 | CTSD (0.51) | CTSDBACE1ADAM17CPB2TERF2 | |
| SCHEMBL23736092 | 0.93 | CTSD (0.44) | CTSDBACE1ADAM17EPHX1CPB2 | |
| SCHEMBL23736353 | 0.89 | CTSD (0.43) | CTSDBACE1ADAM17EPHX1CPB2 | |
| SCHEMBL15727299 | 0.83 | CTSD (0.53) | CTSDBACE1RENTERF2GAA | |
| SCHEMBL15727313 | 0.82 | CTSD (0.43) | CTSDBACE1ADAM17REN | |
| SCHEMBL15727173 | 0.81 | CTSD (0.46) | CTSDBACE1ADAM17RENTERF2 | |
| SCHEMBL15750326 | 0.81 | CTSD (0.46) | CTSDBACE1ADAM17RENTERF2 | |
| SCHEMBL15727316 | 0.78 | CTSD (0.53) | CTSDBACE1TERF2GAA | |
| SCHEMBL15727314 | 0.77 | CTSD (0.55) | CTSDBACE1TERF2GAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9309285-B2 | Macrocyclic broad spectrum antibiotics | RQX PHARMACEUTICALS, INC. (US) | 2016-04-12 | — | — | US | disclosed |
| WO-2014081886-A1 | MACROCYCLIC BROAD SPECTRUM ANTIBIOTICS | RQX PHARMACEUTICALS, INC. (US) | 2014-05-30 | — | — | WO | disclosed |
| US-20140142029-A1 | MACROCYCLIC BROAD SPECTRUM ANTIBIOTICS | RQX PHARMACEUTICALS, INC. (US) | 2014-05-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140142029-A1 | MACROCYCLIC BROAD SPECTRUM ANTIBIOTICS | MRPL21, PEPD, CTSC | CTSD 271/4885BACE1 44/4885ADAM17 71/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.